More interestingly, the IMpower150 trial demonstrated that adding PD-L1 inhibitor atezolizumab to bevacizumab plus chemotherapy with carboplatin and paclitaxel in first line setting significantly improved PFS and OS among patients with advanced nonsquamous NSCLC, regardless of EGFR or ALK mutations and PD-L1 expression status.36 This evidence concerns the gene ALK and non-small cell lung carcinoma.